AORT Logo

Artivion, Inc. (AORT) 

NYSE
Market Cap
$1.24B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
438 of 776
Rank in Industry
57 of 100

Largest Insider Buys in Sector

AORT Stock Price History Chart

AORT Stock Performance

About Artivion, Inc.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment …

Insider Activity of Artivion, Inc.

Over the last 12 months, insiders at Artivion, Inc. have bought $0 and sold $5.41M worth of Artivion, Inc. stock.

On average, over the past 5 years, insiders at Artivion, Inc. have bought $423,204 and sold $2.9M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 15,000 shares for transaction amount of $260,400 was made by SEMEDO ANTHONY B. (director) on 2021‑11‑29.

List of Insider Buy and Sell Transactions, Artivion, Inc.

2024-10-01SaleVP, Chief Accounting Officer
12,430
0.0302%
$26.18$325,415+0.53%
2024-08-26SaleSVP, General Counsel
3,167
0.0076%
$26.55$84,096-1.26%
2024-08-16SaleVP, Human Resources
9,420
0.0228%
$25.31$238,434-0.32%
2024-08-15SaleSVP, General Counsel
2,383
0.0059%
$25.76$61,3930.00%
2024-08-13Saledirector
9,709
0.0232%
$24.99$242,6280.00%
2024-05-10SaleSVP, General Counsel
1,250
0.003%
$23.42$29,275+7.44%
2024-05-09SaleSVP, General Counsel
979
0.0024%
$23.79$23,286+7.92%
2024-03-20SaleSVP, Clinical & MD Affair
2,183
0.0052%
$20.39$44,511+15.02%
2024-03-15SaleVP Regulatory
1,462
0.0036%
$20.00$29,240+20.42%
2024-03-14SaleVP Regulatory
3,994
0.0097%
$20.00$79,880+18.37%
2024-03-12SaleVP, Human Resources
5,000
0.0121%
$19.94$99,720+18.86%
2024-03-05SalePresident & CEO
13,996
0.0343%
$18.72$262,037+27.53%
2024-03-05SaleSVP, General Counsel
2,380
0.0058%
$18.72$44,559+27.53%
2024-03-05SaleChief Commercial Officer
2,022
0.005%
$18.72$37,856+27.53%
2024-03-05SaleVP, Chief Accounting Officer
1,152
0.0028%
$18.72$21,568+27.53%
2024-03-05SaleSVP, Clinical & MD Affair
1,506
0.0037%
$18.72$28,195+27.53%
2024-03-05SaleVP, Human Resources
1,157
0.0028%
$18.72$21,661+27.53%
2024-03-05SaleVP Regulatory
1,160
0.0028%
$18.72$21,718+27.53%
2024-03-05SaleVP, Quality
1,157
0.0028%
$18.72$21,662+27.53%
2024-03-01SaleSVP, Clinical & MD Affair
1,506
0.0036%
$18.72$28,195+24.08%

Insider Historical Profitability

29.7%
Mackin James PPresident & CEO
706038
1.6853%
$29.64416+33.26%
Davis John EChief Commercial Officer
165690
0.3955%
$29.64216+28.47%
SEMEDO ANTHONY B.director
34159
0.0815%
$29.6411+9.19%
LEE DAVID ASHLEYExecutive VP, COO & CFO
347217
0.8288%
$29.64219+25.04%
Bullock Jamesdirector
34023
0.0812%
$29.6410+47.76%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$142.64M16.156.74M-1.51%-$2.19M<0.01
Macquarie Group$59.21M6.712.8M-2.63%-$1.6M0.05
Perceptive Advisors$56.48M6.42.67M+186.57%+$36.77M0.04
The Vanguard Group$56.39M6.392.66M+1.29%+$719,059.12<0.01
Morgan Stanley$49.44M5.62.34M-1.86%-$936,478.50<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.